stockrowBelite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
- EPS
- −40.0%
- Free cash flow
- +64.7%
Quarter to June 2026, against a year earlier
Follow BLTE
Alert me
Belite Bio, Inc. Sponsored ADR (BLTE) Return on equity
Belite Bio, Inc. Sponsored ADR's return on equity over the twelve months to 30 June 2026 was 0.00%, up 16.9 percentage points from fiscal 2025 (−16.9%). Over the past ten years it has ranged from −95.8% (fiscal 2022) to 87.4% (fiscal 2021); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −16.9% | 13.66 |
| FY2024 | −30.6% | 17.35 |
| FY2023 | −48.0% | 47.84 |
| FY2022 | −95.8% | (183.15) |
| FY2021 | 87.4% | 87.36 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 61.1% |
| LGND Ligand Pharmaceuticals Incorporated compare | 5.38% |
| BLTE Belite Bio, Inc. Sponsored ADR | 0.00% |
| ORKA Oruka Therapeutics, Inc. compare | −18.3% |
| CGON CG Oncology, Inc. compare | −26.4% |
| IMVT Immunovant, Inc. compare | −80.1% |
| IONS Ionis Pharmaceuticals, Inc. compare | −105.5% |
| KOD Kodiak Sciences Inc. compare | −368.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −760.0% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)